{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:12:50Z","timestamp":1791231170604,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T00:00:00Z","timestamp":1610064000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T00:00:00Z","timestamp":1610064000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R03 CA199383"],"award-info":[{"award-number":["R03 CA199383"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["KL2TR001454"],"award-info":[{"award-number":["KL2TR001454"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["TL1TR01454"],"award-info":[{"award-number":["TL1TR01454"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s00277-021-04400-7","type":"journal-article","created":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T10:03:13Z","timestamp":1610100193000},"page":"855-863","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Risk factors for monoclonal gammopathy of undetermined significance: a systematic review"],"prefix":"10.1007","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2376-7656","authenticated-orcid":false,"given":"Maira A.","family":"Castaneda-Avila","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine M.","family":"Ulbricht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara Meyer","family":"Epstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,8]]},"reference":[{"key":"4400_CR1","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1034\/j.1600-065X.2003.00056.x","volume":"194","author":"RA Kyle","year":"2003","unstructured":"Kyle RA, Rajkumar SV (2003) Monoclonal gammopathies of undetermined significance: a review. Immunol Rev 194:112\u2013139","journal-title":"Immunol Rev"},{"key":"4400_CR2","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1182\/asheducation.V2012.1.595.3798563","volume":"2012","author":"G Merlini","year":"2012","unstructured":"Merlini G, Palladini G (2012) Differential diagnosis of monoclonal gammopathy of undetermined significance. Hematology Am Soc Hematol Educ Program 2012:595\u2013603","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"4400_CR3","doi-asserted-by":"publisher","unstructured":"Rajkumar SV (2005) MGUS and smoldering multiple myeloma: update on pathogenesis, natural history, and management. Hematology Am Soc Hematol Educ Program:340\u2013345. https:\/\/doi.org\/10.1182\/asheducation-2005.1.340","DOI":"10.1182\/asheducation-2005.1.340"},{"key":"4400_CR4","doi-asserted-by":"publisher","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","volume":"113","author":"O Landgren","year":"2009","unstructured":"Landgren O et al (2009) Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 113:5412\u20135417","journal-title":"Blood"},{"key":"4400_CR5","doi-asserted-by":"publisher","first-page":"5418","DOI":"10.1182\/blood-2008-12-195008","volume":"113","author":"BM Weiss","year":"2009","unstructured":"Weiss BM, Abadie J, Verma P, Howard RS, Kuehl WM (2009) A monoclonal gammopathy precedes multiple myeloma in most patients. Blood 113:5418\u20135422","journal-title":"Blood"},{"key":"4400_CR6","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1158\/1055-9965.EPI-12-1348","volume":"22","author":"LR Goldin","year":"2013","unstructured":"Goldin LR, McMaster ML, Caporaso NE (2013) Precursors to lymphoproliferative malignancies. Cancer Epidemiol Biomark Prev 22:533\u2013539","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"4400_CR7","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1053\/j.seminhematol.2010.11.003","volume":"48","author":"A Zingone","year":"2011","unstructured":"Zingone A, Kuehl WM (2011) Pathogenesis of monoclonal gammopathy of undetermined significance and progression to multiple myeloma. Semin Hematol 48:4\u201312","journal-title":"Semin Hematol"},{"key":"4400_CR8","doi-asserted-by":"publisher","first-page":"933","DOI":"10.4065\/mcp.2010.0337","volume":"85","author":"RK Wadhera","year":"2010","unstructured":"Wadhera RK, Rajkumar SV (2010) Prevalence of monoclonal gammopathy of undetermined significance: a systematic review. Mayo Clin Proc 85:933\u2013942","journal-title":"Mayo Clin Proc"},{"key":"4400_CR9","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1056\/NEJMoa054494","volume":"354","author":"RA Kyle","year":"2006","unstructured":"Kyle RA et al (2006) Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 354:1362\u20131369","journal-title":"N Engl J Med"},{"key":"4400_CR10","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1016\/S0025-6196(11)61089-6","volume":"82","author":"O Landgren","year":"2007","unstructured":"Landgren O et al (2007) Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana. Mayo Clin Proc 82:1468\u20131473","journal-title":"Mayo Clin Proc"},{"key":"4400_CR11","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1182\/blood-2005-08-3449","volume":"107","author":"O Landgren","year":"2006","unstructured":"Landgren O et al (2006) Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. Blood 107:904\u2013906","journal-title":"Blood"},{"key":"4400_CR12","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1182\/blood-2008-12-191676","volume":"114","author":"O Landgren","year":"2009","unstructured":"Landgren O et al (2009) Risk of plasma cell and lymphoproliferative disorders among 14621 first-degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance in Sweden. Blood 114:791\u2013795","journal-title":"Blood"},{"key":"4400_CR13","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1158\/1055-9965.EPI-13-0695","volume":"23","author":"CM McShane","year":"2014","unstructured":"McShane CM et al (2014) Prior autoimmune disease and risk of monoclonal gammopathy of undetermined significance and multiple myeloma: a systematic review. Cancer Epidemiol Biomark Prev 23:332\u2013342","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"4400_CR14","doi-asserted-by":"publisher","first-page":"5359","DOI":"10.1182\/blood-2011-11-387324","volume":"119","author":"AJ Greenberg","year":"2012","unstructured":"Greenberg AJ, Rajkumar SV, Vachon CM (2012) Familial monoclonal gammopathy of undetermined significance and multiple myeloma: epidemiology, risk factors, and biological characteristics. Blood 119:5359\u20135366","journal-title":"Blood"},{"key":"4400_CR15","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.3324\/haematol.2009.010066","volume":"94","author":"SY Kristinsson","year":"2009","unstructured":"Kristinsson SY et al (2009) Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: a population-based study. Haematologica 94:1714\u20131720","journal-title":"Haematologica"},{"key":"4400_CR16","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1056\/NEJMoa01133202","volume":"346","author":"RA Kyle","year":"2002","unstructured":"Kyle RA et al (2002) A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 346:564\u2013569","journal-title":"N Engl J Med"},{"key":"4400_CR17","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.ejim.2010.08.010","volume":"21","author":"H Gregersen","year":"2010","unstructured":"Gregersen H et al (2010) Survival of cancer patients with prior monoclonal gammopathy of undetermined significance. Eur J Intern Med 21:564\u2013568","journal-title":"Eur J Intern Med"},{"key":"4400_CR18","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1046\/j.1365-2141.2001.02533.x","volume":"112","author":"H Gregersen","year":"2001","unstructured":"Gregersen H et al (2001) Mortality and causes of death in patients with monoclonal gammopathy of undetermined significance. Br J Haematol 112:353\u2013357","journal-title":"Br J Haematol"},{"key":"4400_CR19","doi-asserted-by":"publisher","first-page":"391","DOI":"10.7861\/clinmedicine.18-5-391","volume":"18","author":"C Atkin","year":"2018","unstructured":"Atkin C, Richter A, Sapey E (2018) What is the significance of monoclonal gammopathy of undetermined significance? Clin Med 18:391\u2013396","journal-title":"Clin Med"},{"key":"4400_CR20","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1365-2141.2010.08207.x","volume":"150","author":"JR Berenson","year":"2010","unstructured":"Berenson JR et al (2010) Monoclonal gammopathy of undetermined significance: a consensus statement. Br J Haematol 150:28\u201338","journal-title":"Br J Haematol"},{"key":"4400_CR21","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1200\/JCO.2017.35.8_suppl.12","volume":"35","author":"E Maiese","year":"2017","unstructured":"Maiese E, Evans K, Chu B-C, Irwin DE (2017) Trends in survival and costs among U.S. patients with multiple myeloma. J Clin Oncol 35:12\u201312","journal-title":"J Clin Oncol"},{"key":"4400_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2046-4053-4-1","volume":"4","author":"D Moher","year":"2015","unstructured":"Moher D et al (2015) Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 4:1","journal-title":"Syst Rev"},{"key":"4400_CR23","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/2046-4053-1-2","volume":"1","author":"A Booth","year":"2012","unstructured":"Booth A et al (2012) The nuts and bolts of PROSPERO: an international prospective register of systematic reviews. Syst Rev 1:2","journal-title":"Syst Rev"},{"key":"4400_CR24","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1136\/jech.52.6.377","volume":"52","author":"SH Downs","year":"1998","unstructured":"Downs SH, Black N (1998) The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health 52:377\u2013384","journal-title":"J Epidemiol Community Health"},{"key":"4400_CR25","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1161\/CIRCOUTCOMES.113.000121","volume":"6","author":"AM Hajduk","year":"2013","unstructured":"Hajduk AM, Kiefe CI, Person SD, Gore JG, Saczynski JS (2013) Cognitive change in heart failure: a systematic review. Circ Cardiovasc Qual Outcomes 6:451\u2013460","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"4400_CR26","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/ajh.24355","volume":"91","author":"B Boursi","year":"2016","unstructured":"Boursi B, Weiss BM, Haynes K, Mamtani R, Yang Y-X (2016) Reappraisal of risk factors for monoclonal gammopathy of undetermined significance. Am J Hematol 91:581\u2013584","journal-title":"Am J Hematol"},{"key":"4400_CR27","doi-asserted-by":"publisher","first-page":"3388","DOI":"10.1182\/blood-2007-10-121285","volume":"111","author":"LM Brown","year":"2008","unstructured":"Brown LM, Gridley G, Check D, Landgren O (2008) Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders. Blood 111:3388\u20133394","journal-title":"Blood"},{"key":"4400_CR28","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1182\/blood-2010-01-262394","volume":"116","author":"O Landgren","year":"2010","unstructured":"Landgren O et al (2010) Obesity is associated with an increased risk of monoclonal gammopathy of undetermined significance among black and white women. Blood 116:1056\u20131059","journal-title":"Blood"},{"key":"4400_CR29","doi-asserted-by":"publisher","first-page":"6284","DOI":"10.1182\/blood-2011-04-347559","volume":"118","author":"EK Lindqvist","year":"2011","unstructured":"Lindqvist EK et al (2011) Personal and family history of immune-related conditions increase the risk of plasma cell disorders: a population-based study. Blood 118:6284\u20136291","journal-title":"Blood"},{"key":"4400_CR30","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1002\/(SICI)1096-8652(199607)52:3<217::AID-AJH15>3.0.CO;2-C","volume":"52","author":"P Pasqualetti","year":"1996","unstructured":"Pasqualetti P, Collacciani A, Casale R (1996) Risk of monoclonal gammopathy of undetermined significance: a case-referent study. Am J Hematol 52:217\u2013220","journal-title":"Am J Hematol"},{"key":"4400_CR31","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1046\/j.1365-2141.1997.942910.x","volume":"97","author":"P Pasqualetti","year":"1997","unstructured":"Pasqualetti P et al (1997) Tobacco smoking and risk of haematological malignancies in adults: a case-control study. Br J Haematol 97:659\u2013662","journal-title":"Br J Haematol"},{"key":"4400_CR32","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1182\/bloodadvances.2017007609","volume":"1","author":"M Thordardottir","year":"2017","unstructured":"Thordardottir M et al (2017) Obesity and risk of monoclonal gammopathy of undetermined significance and progression to multiple myeloma: a population-based study. Blood Adv 1:2186\u20132192","journal-title":"Blood Adv"},{"key":"4400_CR33","doi-asserted-by":"publisher","first-page":"e0206047","DOI":"10.1371\/journal.pone.0206047","volume":"13","author":"M Thordardottir","year":"2018","unstructured":"Thordardottir M et al (2018) Dietary intake is associated with risk of multiple myeloma and its precursor disease. PLoS One 13:e0206047","journal-title":"PLoS One"},{"key":"4400_CR34","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1056\/NEJMoa021423","volume":"348","author":"EE Calle","year":"2003","unstructured":"Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348:1625\u20131638","journal-title":"N Engl J Med"},{"key":"4400_CR35","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/S0140-6736(08)60269-X","volume":"371","author":"AG Renehan","year":"2008","unstructured":"Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M (2008) Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371:569\u2013578","journal-title":"Lancet"},{"key":"4400_CR36","first-page":"251","volume":"19","author":"BT Blak","year":"2011","unstructured":"Blak BT, Thompson M, Dattani H, Bourke A (2011) Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates. Inform Prim Care 19:251\u2013255","journal-title":"Inform Prim Care"},{"key":"4400_CR37","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1158\/1055-9965.EPI-14-1145","volume":"24","author":"G Andreotti","year":"2015","unstructured":"Andreotti G et al (2015) A pooled analysis of cigarette smoking and risk of multiple myeloma from the international multiple myeloma consortium. Cancer Epidemiol Biomark Prev 24:631\u2013634","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"4400_CR38","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1093\/annonc\/mdv355","volume":"26","author":"JM Genkinger","year":"2015","unstructured":"Genkinger JM et al (2015) Central adiposity, obesity during early adulthood, and pancreatic cancer mortality in a pooled analysis of cohort studies. Ann Oncol 26:2257\u20132266","journal-title":"Ann Oncol"},{"key":"4400_CR39","doi-asserted-by":"publisher","first-page":"e618","DOI":"10.1038\/bcj.2017.97","volume":"7","author":"O Landgren","year":"2017","unstructured":"Landgren O et al (2017) Prevalence of myeloma precursor state monoclonal gammopathy of undetermined significance in 12372 individuals 10\u201349 years old: a population-based study from the National Health and Nutrition Examination Survey. Blood Cancer J 7:e618","journal-title":"Blood Cancer J"},{"key":"4400_CR40","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/pds.4912","volume":"29","author":"MM Epstein","year":"2020","unstructured":"Epstein MM et al (2020) Identifying monoclonal gammopathy of undetermined significance in electronic health data. Pharmacoepidemiol Drug Saf 29:69\u201376","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-021-04400-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-021-04400-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-021-04400-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T06:28:34Z","timestamp":1697524114000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-021-04400-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,8]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["4400"],"URL":"https:\/\/doi.org\/10.1007\/s00277-021-04400-7","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,8]]},"assertion":[{"value":"30 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no potential conflicts of interest. This article does not contain any studies with human participants or animals performed by any of the authors.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}}]}}